register

News & Trends - Medical Technology

Medical association continues its strong opposition to Honeysuckle Health in legal proceedings

Health Industry Hub | June 24, 2022 |
[Total: 1    Average: 5/5]

MedTech News: The Australian Medical Association (AMA) is involved in proceedings before the Australian Competition Tribunal, opposing an attempt by Honeysuckle Health to water down conditions.

Last September the Australian Competition and Consumer Commission (ACCC) issued its final decision on the long running application by nib and Honeysuckle Health seeking authorisation as a buying group.

While the ACCC’s final decision did not reject the application for authorisation, it did accept the AMA’s argument that the original proposal from Honeysuckle Health would give it excessive market power and contravene competition laws. The ACCC imposed significant conditions on the proposed Honeysuckle Health’s buying group, excluding the major private health insurers* from participation, and limiting the authorisation to five years. 

Unfortunately, these hard-won conditions are now under threat with Honeysuckle Health seeking to have them removed, as part of review proceedings currently before the Australian Competition Tribunal.

The AMA is taking an active role in these proceedings and has been granted leave to intervene by the Tribunal. This week saw the AMA lodge documents with the Tribunal which included expert economic evidence, and witness evidence from the AMA President, Dr Omar Khorshid.

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) and by the Australian Pain Society (APS) had also applied for leave to make submissions to the Tribunal in line with AMA’s position. The Tribunal did not grant this saying their arguments would not add anything new or substantial to AMA’s evidence.

Throughout the authorisation process, the AMA opposed the application by Honeysuckle Health, arguing it would have too much market power and exploit this to pursue a managed care agenda. The AMA’s application to intervene restated our opposition to the authorisation and this remains the AMA’s primary position.

If the Tribunal is not prepared to overturn the authorisation, then the AMA said it will argue that the original conditions should not only be maintained, but further strengthened by the inclusion of others to guard against managed care arrangements.

It will be some time before the outcome of this appeal is finalised. More submissions and materials will need to be filed with the Tribunal by the parties over coming months and hearings are not due to start until 1 August 2022.

*In relation to HBF, this exclusion applies only applies in Western Australia


Human Resources

Only 29% of employees say their leader shows ‘human leadership’

Health Industry Hub | June 24, 2022 |

Human Resources: A survey of more than 230 HR leaders revealed that 90% believe that to succeed in today’s work environment, […]

More


News & Trends - Medical Technology

MedTech News - Quantum HealthCare appointed as ANZ distributor for new medical technology

Quantum HealthCare appointed as ANZ distributor for new medical technology

Health Industry Hub | June 24, 2022 |

MedTech News: Alfred Health Hospital in Australia is set to receive first-in-nation portable MRI systems for point-of-care brain scans. US-based […]

More


News & Trends - Medical Technology

Medtech News - Medical association continues its strong opposition to Honeysuckle Health in legal proceedings

Medical association continues its strong opposition to Honeysuckle Health in legal proceedings

Health Industry Hub | June 24, 2022 |

MedTech News: The Australian Medical Association (AMA) is involved in proceedings before the Australian Competition Tribunal, opposing an attempt by […]

More


News & Trends - Medical Technology

Medtech News -

Medtronic award winner secures approval in diagnosis of gut disorders

Health Industry Hub | June 24, 2022 |

MedTech News: New Zealand based company and winner of the inaugural Medtronic APAC Innovation Challenge (MAIC) has received FDA approval […]

More


This content is copyright protected